. They reported a very large current putatively mediated by MCU that was about two orders of magnitude greater than the MCU current (I MCU ) that we previously measured in heart mitochondria 3 ; furthermore, the current traces presented by Joiner et al. showed unusually high fluctuations incompatible with the low single-channel conductance of MCU. Here we performed patchclamp recordings from mouse heart mitochondria under the exact mitoplasts obtained by exposure of mitochondria to 5-min hypotonic shock. Both round (left) and 'figure-8-shaped' (right) mitoplasts were present in this preparation and used for electrophysiological experiments. Arrows indicate remnants of the outer mitochondrial membrane. The average diameter of heart mitoplasts in this preparation is ,4.5 mm (n 5 65), which corresponds well with the average membrane capacitance (C m ) measurements of 0.67 pF that we previously reported. b, Representative heart whole-mitoplast MCU currents (I MCU ) recorded in the presence (left) or absence (middle) of 150 mM Nagluconate in both the pipette and bath solutions. I MCU was recorded with different bath Ca 21 concentrations: 0.2 mM (red), 1 mM (blue) and 105 mM (green). I MCU was blocked by 50 nM RuR added to the 0.2 mM Ca 21 bath solution (control, black). Currents in left and middle panels are not normalized and were recorded from two different mitoplasts with comparable membrane capacitance (C m 5 0.80 pF and 0.84 pF, respectively). The voltage ramp protocol used to elicit I MCU is indicated at the top. With Na 1 in the recording solutions we also observed a small outward current at high positive voltages. This current was absent in Na I MCU amplitude was monitored for up to 35 min after formation of the wholemitoplast configuration as in Joiner et al. 7 (however, the calculated diffusion time 15 for the 35-kDa monomer of CaMKII from the pipette into the mitoplast is only ,25 s). Pipette solution contained (in mM): 150 Na-gluconate, 40 HEPES, 2 NaCl, 1.5 EGTA, tonicity 450 mmol per kg with sucrose, pH 7.2 with NaOH. The recombinant T287D and wild-type CaMKII were added to the control solution at 0.5 or 1 mM, in the presence of 2 mM Na 2 The main differences in the experimental conditions used by Joiner et al. 7 and in our previous study 3 were: the use of hypotonic shock to prepare mitoplasts (versus French press in our study), the presence of high Na 1 concentration in recording solutions (versus Na 1 -free solutions), and the age of the mice (2-3 months versus 3-4 weeks). Figure 1a shows mouse heart mitoplasts obtained by exposure of mitochondria to hypotonic shock. The measured average membrane capacitance (C m ) was 0.65 6 0.03 pF (6 s.e.m., n 5 65), which correlates well with C m measurements reported for heart mitoplasts obtained with French press 3 , as well as with measurements of the inner mitochondrial membrane surface area using electron microscopy 8, 9 and with estimated measurements of idealized cardiac mitochondria 10 . Therefore, the values reported by Joiner et al. 7 seem to be abnormally high (529 pF), indicating inaccuracy in monitoring C m leading to faulty values of I MCU densities throughout the paper.
We recorded I MCU from heart mitoplasts isolated by hypotonic shock with 150 mM Na-gluconate in the pipette and bath solutions (as in Joiner et al.
7
; Fig. 1b, left panel) and without Na 1 (conditions previously used by us 3 ; Fig. 1b, middle panel) . I MCU recorded in the presence of Na-gluconate was significantly smaller than in its absence (Fig. 1b) . Our data support the observation that elevated Na 1 may regulate heart mitochondrial Ca 21 concentration 11, 12 . Notably, the whole-mitoplast I MCU was about two orders of magnitude lower than the current reported by Joiner et al. 7 (,2 pA at 2160 mV in 0.2 mM Ca 21 versus ,180 pA) and did not exhibit high fluctuations as expected for a small-conductance channel. Also, the current reported by Joiner et al. 7 was not inhibited by Ru360 in the same fashion as the I MCU (ref. 2). In 10 nM Ru360, I MCU shows no immediate inhibition upon stepping from 0 mV to 2120 mV (ref. 2) , and the inhibition develops slowly over time 2 , whereas the current of Joiner et al. 7 was inhibited immediately upon stepping from 0 to 2160 mV. All these observations indicate that Joiner et al. 7 did not record I MCU . We suggest that either they did not record from inner mitochondrial membrane or the integrity of their mitoplasts was compromised.
Next, we tested whether I MCU is directly regulated by CaMKII, as claimed by Joiner et al. 7 , who reported that addition of a constitutively active monomeric form of CaMKII (T287D mutant) to the patch pipette potentiated their currents. When we applied T287D mutant CaMKII, we failed to observe any functional change in I MCU , either without (Fig. 1c,  middle panel, and Fig. 1d ) or with Ca 21 plus calmodulin (Fig. 1e) . We further verified these results using wild-type monomeric CaMKII preautophosphorylated with thiol-ATP to prevent de-autophosphorylation and again observed no change in I MCU (Fig. 1c, right panel, and Fig. 1d) .
The noisy currents presented by Joiner et al. 7 do not appear to be carried by MCU, and their extremely high amplitude misrepresents the actual MCU activity in heart. Heart, with abundant mitochondria and frequently elevated cytosolic Ca 21 , has very low MCU current 3 , which is probably critical for avoiding disruption of cytosolic Ca 21 signalling and preventing mitochondrial Ca 21 overload and cell death. Finally, our electrophysiological experiments with MCU currents did not indicate that MCU is regulated by CaMKII.
Methods
Electrophysiological experiments were performed as in ref. 3 . Recombinant dhuman monomeric CaMKII (1-317) was purified from baculovirus using an aminoterminal 63-HN tag and Ni chromatography followed by gel filtration. Activity of recombinant CaMKII was measured in Na-gluconate pipette solution using the peptide substrate AC-2 (ref. 13 -dependent process of heart disease, we used multiple methods to show that CaMKII modulates mitochondrial Ca 21 homeostasis, as outlined below. First, we carried out electrophysiology of the mitochondrial calcium uniporter (MCU) current in mitoplasts. In our report 1 we did not claim to measure capacitance of the mitoplast separately from the total capacitance of the mitoplast and pipette. Although we concede that the approach of Fieni et al.
2 is preferable, we found that even after removing any correction for capacitance, dialysis with constitutively active CaMKII monomers increased MCU current whereas dialysis with catalytically dead CaMKII monomers did not.
Second, we identified candidate CaMKII sites on the MCU amino terminus (serine 57 and serine 92), and used a variety of approaches to provide evidence that both are functional and their phosphorylation by CaMKII increases MCU current. These approaches include transgenic mitochondrial-targeted expression of a highly selective CaMKII inhibitor (mtCaMKIIN), and dialysis of both constitutively active and catalytically inactive control CaMKII in cardiac mitoplasts, as well as in mitoplasts from HEK cells overexpressing wild-type MCU or a mutant form in which the two serines are replaced with alanines (S57A/S92A). We are uncertain why the dialysis by Fieni et al.
2
, which used a constitutively active monomeric form of CaMKII, was ineffective in increasing MCU current, but given the tendency with which this kinase may lose activity we prefer a positive control experiment showing that the introduced CaMKII is active within a biological system. Third, we measured a current from mitoplasts that we believe to be from MCU because: (1) it rectifies inwardly; (2) it displays greater Na 1 than Ca 21 conductance; and (3) it is inhibited by Ru360 (albeit with a different kinetic signature than reported by Fieni et al. ). In addition to the voltage-clamp approach, we measured mitochondrial Ca 21 entry with Ca 21 green-5N dye and mitochondrial-targeted cameleon FRET, which also report on mitochondrial Ca 21 entry via the MCU pathway (that is, MCU current), as confirmed by a recent report on MCU knockout mice 3 . Indeed, mitochondrial Ca 21 uptake measured using Ca 21 green-5N, intramitochondrial Ca 21 sensitive probes and Ca 21 -induced mitochondrial swelling are absent in MCU knockout mice, indicating that these approaches are reporting on MCU current. These approaches, deployed in a variety of systems, corroborated our findings with voltage clamp and supported the role of CaMKII in facilitating mitochondrial Ca 21 entry. Since the time of our publication we have continued to study the role of CaMKII in mitochondria, including work to validate the Ser 57 and Ser 92 sites on MCU further. We note that our ongoing experiments support the concepts outlined in our original paper. The main finding in Joiner et al. was that CaMKII is present in cardiac mitochondria, where it participates in mitochondrial Ca 21 homeostasis and contributes to pathological responses to stress, including myocardial infarction, ischaemia-reperfusion injury and catecholamine toxicity
